Maintenance Notice (3:00 AM - 8:30 AM November 1, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Chemistry News October 2025 | [Product Highlights] Tetraphenylethylene Derivatives Used for... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 155213-67-5 | Product Number: R0116
Ritonavir
×
![]()
×
Purity: >98.0%(HPLC)(N)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 200MG |
$78.00
|
9 | 7 | Contact Us | |
| 1G |
$253.00
|
14 | ≥40 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | R0116 |
Purity / Analysis Method 
|
>98.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__3__7H__4__8N__6O__5S__2 = 720.95 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image), 200MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 155213-67-5 |
| Reaxys Registry Number | 7680098 |
| PubChem Substance ID | 253660208 |
| Merck Index (14) | 8238 |
| MDL Number | MFCD00927142 |
Specifications
| Appearance | White to Almost white powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 122.0 to 127.0 °C |
| Specific rotation [a]20/D | +7.0 to +10.0 deg(C=2,MeOH) |
Properties (reference)
| Melting Point | 125 °C |
| Specific Rotation | 8° (C=2,MeOH) |
| Solubility in water | Insoluble |
| Solubility (slightly sol. in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 + H312 + H332 : Harmful if swallowed, in contact with skin or if inhaled. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P271 : Use only outdoors or in a well-ventilated area. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P302 + P352 + P312 : IF ON SKIN: Wash with plenty of water.Call a POISON CENTER/doctor if you feel unwell. P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell. |
Related Laws:
| RTECS# | XA5310000 |
Transport Information:
| H.S.code* | 2934.10-000 |
Application
Ritonavir: a Booster of Other Protease Inhibitors
Ritonavir was originally developed as an inhibitor of HIV protease inhibitor (PI). Ritonavir is currently exclusively used as a pharmacokinetic enhancer (booster) of other protease inhibitors, due to ritonavir's potent inhibition of the cytochrome P 450 3A4 (CYP3A4), an enzyme that is responsible for metabolizing most HIV PIs.
References
- A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
- A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
- Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
- Pharmacokinetic enhancers for HIV drugs
- M. W. Hull, J. S. G. Montaner, Curr. Opin. Invest. Drugs 2009, 10, 775.
- Ritonavir-boosted protease inhibitors in HIV therapy
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.